Prenetics Global Announces Closing Of $1B In Growth Financing From General Catalyst’s Customer Value Fund; Co. Raises FY26 IM8 Revenue Guida

IM8 is the fastest-growing premium supplement brand ever recorded — over 50 million servings delivered to date, with approximately 200,000 servings currently delivered daily, and an order every 27 seconds Prenetics raises full-year 2026 IM8 revenue guidance to $210–220 million, up from $190–210 million IM8 expected to reach $300 million in annualized run-rate revenue by year-end 2026 IM8 expected to deliver $400 million or more in full-year 2027 revenue Every $1 invested in customer acquisition has returned $1.44 in gross profit, blended across all mature cohorts NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE ) ("Prenetics" or the "Company"), a leading consumer health company and parent of the AI-native direct-to-consumer wellness brand IM8, co-founded by David Beckham, today announced the closing of $1 billion in growth financing from General Catalyst’s Customer Value Fund ("CVF").

Under the arrangement, General Catalyst’s Customer Value Fund will finance up to 70% of IM8’s marketing spend, with IM8 retaining full discretion over facility utilization.

In return, General Catalyst will receive a capped share of income that is tied to the performance of customer cohorts financed through the program, capped at predetermined levels.

Once General Catalyst has recovered its investment and capped return on any given monthly cohort, all subsequent value from those customers accrues entirely and permanently to IM8.

The arrangement does not involve the issuance of any equity, warrants, or convertible instruments to General Catalyst, and is tracked separately for each monthly cohort of customers.